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Background: Glutamic acid decarboxylase (GAD) is the rate-limiting enzyme in the synthesis of γ-aminobutyric acid
(GABA). Anti-GAD antibodies (GADA) are associated with the progression of stiff person syndrome and other
neurological diseases, as well as the immune-mediated (type 1) diabetes. GABA is one of the most widely
distributed neurotransmitters, but the non-motor symptoms of GADA-positive patients are not well understood.
Diabetes is increasingly recognized as a risk factor for dementia; however, the relationship between diabetes and
dementia is controversial.
The objective of this study was to assess cognitive function in patients with GADA-positive diabetes using subjects
with GADA-negative type 2 diabetes as controls.
Methods: Twenty-one patients with GADA-positive diabetes (mean age 52.5 ± 12.3 years, mean duration 7.7 ± 6.6
years) and 19 control subjects with GADA-negative type 2 diabetes (mean age 53.4 ± 8.9 years, mean duration 12.5 ±
6.7) were included in the study. The subjects underwent extensive neuropsychological testing and brain MRI.
Results: The neuropsychological test scores were lower in the GADA-positive group than the control group
(GADA-negative). Twelve subjects (57%) in the GADA group and 4 subjects (21%) in the control group had low
performances (p = 0.027). No statistically significant differences were found between the GADA and control groups
regarding demographics, diabetic severity cardiovascular risks, cerebral T2 hyperintensities, white matter volume and
gray matter volume.
Conclusions: Our study showed that GADA-positive diabetic patients have an increased risk of cognitive decline
compared to patients with type 2 diabetes of comparable diabetic severity. It also showed that GADA may be
associated with isolated cognitive decline in the absence of other neurological complications.
Keywords: Anti-glutamic acid decarboxylase antibodies, Diabetes mellitus, Stiff-person syndrome,
Cognitive impairment, GABAergic neural system, Voxel-based morphometryBackground
Glutamic acid decarboxylase (GAD) is the rate-limiting
enzyme in the synthesis of γ-aminobutyric acid (GABA),
a major inhibitory neurotransmitter that modulates and
synchronizes neural network activity in the CNS [1].
Two isoforms of the enzyme, GAD65 and GAD67, are
found in the CNS. Autoantibodies (GADA) against* Correspondence: mastakagi@med.tohoku.ac.jp
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reproduction in any medium, provided the orGAD65 inhibit the activity of GAD65 and therefore im-
pair GABA synthesis. Various neurological manifesta-
tions are associated with GADA, including stiff person
syndrome (SPS), cerebellar ataxia, epilepsy, and limbic
encephalitis [2]. Intrathecal GADA synthesis induces
symptoms in the CNS, presumably by affecting the
GABAergic system [3], which is involved in cognitive
function. However, little is known regarding the relation-
ship between GADA and cognitive impairment.
Serum GADA play a role in the pathogenesis of the
immune-mediated (type 1) diabetes [4-6]. Immune-Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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betes [7], and GADA was found in 92% of adult auto-
immune diabetic patients [8]. Diabetic patients are at risk
for dementia [9-11], especially vascular dementia, and
Alzheimer’s disease [12,13]. We recently encountered a
patient with GADA-positive diabetes who presented with
language problems, short-term memory disturbance, and
frontal dysfunction without any other neurological deficits,
suggesting that GADA may cause dementia [14]. This
observation led to the hypothesis that GADA cause cogni-
tive deficits in patients with immune-mediated diabetes.
To determine whether GADA are an independent risk fac-
tor for dementia, we assessed cognitive function in pa-
tients with GADA-positive diabetes and GADA-negative




We assessed 23 patients with GADA who presented at
the outpatient clinic of our hospital between July 2010
and August 2011. Patients were selected according to
the following criteria: adult-onset (after age 20) GADA-
positive diabetes; no previous history of neurological dis-
orders, including stroke, dementia, or severe psychiatric
disorders; no contraindications for MRI; sufficient ability
to take neuropsychological tests; no use of psychotropic
medications; and an MRI free of major-artery stroke,
strategic-infarct, and space-occupying lesions. Two pa-
tients were excluded because they had been diagnosed
with GADA-associated neurological disorders (one the
patient with cerebellar ataxia (GADA titer = 11300 U/
ml) and one the patient with limbic encephalitis (GADA
titer = 15200 U/ml)). Thus, 21 patients with GADA were
included in this study (denoted the GADA group).
As a control group, we assessed individuals with type
2 GADA-negative diabetes. We stratified the GADA-
positive subjects according to age, dividing into 3 age-
groups (35-49, 50-64, and greater than 65 years). Control
subjects corresponding to the age-range were chosen
and were paired with a GADA-positive subject based on
the severity of their hyperglycemia, which is represented
by HbA1c values. Inclusion and exclusion criteria were
the same as described for the GADA group.
The study was approved by the Medical Ethics Com-
mittee of Tohoku University Graduate School of Medi-
cine and was conducted in accordance with the ethical
standards established in the Declaration of Helsinki.
Prior to the beginning of the study, written consent was
obtained from each participant.
Medical backgrounds
At the time of entry into the study, each subject under-
went a structured, in-person interview of health andfunction, followed by the completion of a standard med-
ical history form, physical and neurological examinations,
and a series of neuropsychological tests. The subjects’
medical records were examined for their most recent
medical conditions and comorbid conditions. In regards
to diabetic microangiopathies, any stage of retinopathy
was counted. We defined diabetic neuropathy as self-
awareness of peripheral sensory or motor neuropathy after
developing diabetes. Diabetic nephropathy was defined as
microalbuminuria, persistent proteinuria, or increased
serum creatinine that could not be explained by any other
kidney disease. Information on hypertension, dyslipidemia,
smoking habits, insulin use, severe hypoglycemic episodes
[15], and HbA1c values were self-reported and were con-
firmed by their medical records. Years of education were
self-reported. Serum GADA titers were measured using a
commercially available kit (Cosmic Corporation, Tokyo,
Japan), that provides a specific and sensitive method for
evaluating GAD antibodies [16].
Neurological examination and neuropsychological
evaluation
Global cognitive function was assessed with the Mini-
Mental State Examination (MMSE) [17]. Intellectual
ability was measured using the Japanese version of the
Wechsler Adult Intelligence scale, 3rd edition (WAIS-
III), which yields 3 IQ scores (full scale IQ (FIQ), per-
formance IQ (PIQ), and verbal IQ (VIQ)) and 4 index
scores (verbal comprehension (VC), perceptual orga-
nization (PO), working memory (WM), and processing
speed (PS)). Memory function was assessed using the lo-
gical memory test (LMT), a sub-test that was derived
from the Japanese version of the revised Wechsler Mem-
ory Scale (WMS-R), and the Rey Osterrieth Complex
Figure Test (RCFT). Verbal fluency tests (VF) and the
trail-making test (TMT) were used as measures of
executive function. We also used the digit span test de-
rived from the WAIS-III for evaluating sustained atten-
tion, and we administered a Stroop test to assess
directed attention. We asked the housemates of the sub-
jects to fill out Japanese versions of the Neuropsychiatric
Inventory Questionnaire (NPI-Q) [18], a validated clin-
ical instrument for evaluating the behavioral and psycho-
logical symptoms of dementia.
MRI data acquisition and analysis
All of the patients underwent brain MRI (1.5-Tesla;
Signa, General Electric Medical Systems, Milwaukee,
WI) within a month of the neuropsychological eva-
luation. The MRI protocols included axial T2-weighted
(repetition time, 4750 ms; echo time, 95.0 ms; matrix
size, 320 × 224; field of view, 210 mm; slice thickness,
6 mm), fluid attenuated inversion-recovery sequence
(repetition time, 11000 ms; echo time, 110.0 ms; inversion
Table 1 Demographic data
Variables GADA Control
(n = 21) (n = 19)
Mean Age, y (SD) 52.5 (12.3) 53.4 (8.9)
Sex ratio (F:M) 14:7 11:8
Education, y (SD) 13.1 (2.9) 13.1 (2.1)
Mean disease duration, y (SD) 7.7 (6.6) 12.5 (6.7) *
Mean HbA1c value, % (SD) 7.9 (1.6) 7.4 (1.3)
Mean daily insulin dose, units (SD) 36.2 (32.2) 23.5 (25.5)
Insulin index, units/kg/day (SD) 0.6 (0.4) 0.3 (0.3)
Weight, kg (SD) 60.8 (12.5) 72.5 (15.6) *
Height, m (SD) 1.62 (9.8) 1.62 (8.9)
BMI, kg/m2 (SD) 23.4 (5.5) 27.4 (4.9) *
Insulin index - units of insulin taken in a 24-h period divided by weight in kg.
Abbreviations: GADA glutamic acid decarboxylase antibody, BMI body mass
index (weight in kg divided by height in m2).
* p < 0.05.
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mm; slice thickness, 6 mm), and T1-weighted 3-dimen-
sional spoiled gradient echo (3-D SPGR) scans (repetition
time, 20 ms; echo time, 4.1 ms; number of acquisition, 1;
flip angle, 30°; field of view, 250 mm; matrix size, 256 ×
256; slice thickness, 1.5 mm). The MRI data were carefully
inspected to detect ineligible participants and were evalu-
ated by a trained neurologist (KI) who was blinded to
patient history. Cerebral infarcts were defined as focal
hyperintensities (3 mm in size or larger) on T2-weighted
images with a corresponding prominent hypointensity on
T1-weighted images [19]. The severity of the T2 signal
hyperintensity lesions was assessed using the scale des-
cribed by Scheltens et al. [20]. The semi-quantitative
rating method was used to assess periventricular hyper-
intensities (PVH), white matter hyperintensities (WMH),
basal ganglia hyperintensities (BGH), and infratentorial
foci (ITF). The total score and sub-scores were used for
analyses. To compare the gray matter volumes between
the 2 groups, we performed voxel-based morphometry.
The 3-D SPGR data were analyzed with SPM8 software
(Wellcome Department of Cognitive Neurology, Institute of
Neurology, London) running on Matlab 2008a (Math-Works,
Natick, MA, USA). We used the VBM8 toolbox (http://dbm.
neuro.uni-jena.de/vbm.html) with default parameters.
The images were bias-corrected, tissue classified, and
registered using linear (12-parameter affine) and non-
linear transformations [21]. Next, analyses were performed
on the gray matter volume (GMV) and white matter vol-
ume (WMV), which were then multiplied by the non-
linear components derived from the normalization matrix
to locally preserve actual gray matter and white matter
values respectively. Finally, the modulated volumes were
smoothed with a Gaussian kernel of 8 mm full width at
half maximum. Voxel-wise differences between the groups
were examined using independent sample t-tests. To avoid
possible edge effects between different tissue types, we ex-
cluded all voxels with gray matter values of less than 0.2
(absolute threshold masking). We applied a threshold of p
< 0.001 with an extent of 5 voxels across the whole brain.
Age, disease duration, and total intracranial volume (TIV)
were used as covariates, meaning that all of the effects that
could be explained by these parameters were removed
from the data. TIV was computed from the 3 components
of global tissue volume; GMV, WMV, and CSF, which
were determined by counting the voxels in native dimen-
sions. The volumes of GMV, WMV and TIV were used to
calculate the ratio of GMV or WMV to TIV in each
subject.
Statistical analysis
The data were analyzed using SPSS for Windows (Version
19, IBM SPSS Statistics, Chicago, IL). The differences in
the baseline data and neuropsychological test performancebetween the GADA and control groups were assessed with
independent sample t-tests, Mann–Whitney U tests, or
Fisher exact tests, as appropriate. Spearman rank correla-
tions were calculated for the GADA titer and the results
of cognitive tests. All of the statistical tests were 2-tailed,
and the results were considered significant at a level of
p < 0.05. No adjustment was made for multiple compari-
sons because of the exploratory nature of the study. The
relative risk of low cognitive performance in the GADA
group versus the control group was calculated according
to the number of low performers in each group. WAIS-III
sub-scales and memory-related tests (LMT and RCFT)
were considered major outcome measures. Low per-
formers were defined as those whose IQ scores or indices
were less than 80, which represents the lower normal limit
of each sub-scale in WAIS-III. Age-adjusted cut-off points




The baseline characteristics of the subjects are shown in
Table 1. Female subjects represented 66.7% of the sub-
jects in the GADA group and 57.9% of the subjects in
the control group. The 2 groups were well balanced for
age, years of education, and HbA1c values. The diabetes
disease duration, body weight, and body mass index
were greater in the control group. The required insulin
dose and insulin index (insulin doses per body weight)
were not significantly different between the groups. The
number of complications varied between the groups, but
the difference was not significant (Table 2). Fewer
patients in the GADA group had hypertension or
dyslipidemia. The prevalence of diabetic microangiopathies
was comparable between the groups. Severe hypoglycemic
Table 3 Neuropsychological test scores and NPI-Q scores
(mean (SD))
GADA Control p-values
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in the GADA group ranged from 3.3 to 14,000 U/ml
(median = 30.15 U/ml).(n = 21) (n = 19)
Global cognitive functioning
MMSE 28.8 (1.7) 29.1 (1.4) 0.63
Intellectual ability (WAIS-III)
FIQ 94.0 (16.2) 105.8 (11.8) 0.01
VIQ 96.0 (16.3) 107.2 (13.9) 0.03
PIQ 92.8 (16.2) 100.5 (12.1) 0.10
VC 97.6 (14.4) 106.0 (13.9) 0.07
PO 93.5 (14.4) 102.5 (10.6) 0.03Neurological examination
None of the subjects had subjective symptoms including
oscillopsia. However, abnormal eye motion, character-
ized by a discordant horizontal pursuit and a difficulty in
maintaining horizontal gaze, was detected in 2 (10%) out
of 21 patients with GADA. A similar eye movement dis-
order was noted in the patient with GADA-associated
cerebellar ataxia, who was excluded from the study, but
was not seen in any of the patients in the control group.WM 93.6 (17.6) 99.7 (11.6) 0.20
PS 94.0 (16.0) 96.5 (13.7) 0.61
Attention
Digit Span, forward 6.3 (1.3) 6.8 (1.2) 0.15
Digit Span, backward 5.0 (1.5) 4.8 (1.0) 0.78
Stroop Test 145.5 (82.0) 112.4 (39.3) 0.11
Memory
LMT, immediate 23.8 (8.6) 26.3 (7.8) 0.34
LMT, delay 19.0 (7.7) 23.0 (7.5) 0.11
RCFT, copy 34.7 (2.7) 35.5 (1.2) 0.28
RCFT, immediate 19.1 (10.1) 23.8 (5.2) 0.07
RCFT, delay 18.5 (9.7) 23.8 (4.8) 0.03
RCFT, recognition 19.9 (2.1) 20.6 (2.1) 0.29
Executive functions
VF, phonemic (Fu/A/Ni) 24.6 (7.3) 31.3 (8.2) 0.009
VF, category (Animal) 16.9 (4.1) 17.6 (4.2) 0.56
TMT, part A 49.4 (18.3) 45.1 (15.1) 0.43
TMT, part B 151.3 (122.0) 108.6 (66.2) 0.17
Neuropsychiatric state
NPI-Q severity† 1.2 (2.0) 0.4 (0.9) 0.36
NPI-Q distress† 1.2 (2.5) 0.2 (0.5) 0.28
Higher scores indicate better performance on all of the neuropsychologicalNeuropsychological assessment
Table 3 shows the results of the neuropsychological as-
sessments. The WAIS-III showed significant differences
in 3 sub-scales: the FIQ (GADA 94.0 ± 16.2, control
105.8 ± 11.8, p = 0.01), VIQ (GADA 96.0 ± 16.3, control
107.2 ± 13.9, p = 0.03), and PO (GADA 93.5 ± 14.4, con-
trol 102.5 ± 10.6, p = 0.03) scores were lower in the
GADA group than in the control group. On the WAIS-
III, 10 GADA-positive subjects and 4 control subjects
were low performers, but the difference was insignificant
(p = 0.105). All the subjects in both group performed
better than the age-adjusted cut-off point on the LMT
and on the RCFT tests, but 8 subjects only in the GADA
group achieved scores below the cut-off point in the
RCFT delayed-recall test (p = 0.004). The average scores
for the RCFT delayed-recall test (GADA 18.5 ± 9.7, con-
trol 23.8 ± 4.8, p = 0.03) were significantly lower in the
GADA group than in the control group. Collectively, 12
subjects (57%) in the GADA group and 4 subjects (21%)
in the control group had low performances on at least
one major outcome measure (p = 0.027). The relative
risk for cognitive decline was 2.71 (95% CI = 1.05-6.99)
in the GADA group. In addition, phonemic verbal flu-
ency was lower in the GADA group than in the controlTable 2 Number (%) of cases with complications
Variables GADA Control
(n = 21) (n = 19)
Hypertension, n (%) 9 (43%) 12 (63%)
Dyslipidemia, n (%) 8 (38%) 10 (53%)
Current smoker, n (%) 2 (10%) 3 (15%)
Diabetic retinopathy, n (%) 3 (14%) 5 (26%)
Diabetic nephropathy, n (%) 4 (19%) 8 (42%)
Diabetic neuropathy, n (%) 4 (19%) 5 (26%)
Small vessel disease on MRI, n (%) 3 (14%) 5 (26%)
Fisher exact tests showed no significant differences.
Abbreviations: GADA glutamic acid decarboxylase antibody.
tests except for the trail-making test and the Stroop test, in which higher
scores indicate worse performance. High NPI-Q scores reflect worse
neuropsychiatric status.
Abbreviations: GADA glutamic acid decarboxylase antibody, LMT logical
memory test, RCFT Rey Osterrieth complex figure test, VF verbal fluency tests,
TMT trail making test, NPI-Q neuropsychiatric inventory questionnaire.
† Mann-Whitney U test.group (GADA 24.6 ± 7.3, control 31.3 ± 8.2, p = 0.009).
In the GADA group, the GADA titer was not signifi-
cantly correlated with any of the neuropsychological
assessments.
Psychiatric assessment
The NPI-Q showed a neuropsychiatric feature of GADA
group, but the differences between the 2 groups did not
reach statistical significance. Six subjects (29%) in the
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points, and 4 subjects (21%) in the control group scored
from 1 to 3 points. Four neuropsychiatric symptom
domains were positive only in the GADA group: delu-
sions (n = 1), agitation/aggression (n = 2), euphoria/ela-
tion (n = 1), and apathy/indifference (n = 2). Five other
domains were positive in small numbers of patients in
both groups: dysphoria/depression (GADA, n = 3; con-
trol, n = 1), anxiety (GADA, n = 2; control, n = 2), disin-
hibition (GADA, n = 1; control, n = 1), irritability/
lability (GADA, n = 4; control, n = 2), nighttime behav-
ioral disturbances (GADA, n = 1; control, n = 1). The
appetite/eating disturbances domain was positive in a
patient in the control group. Hallucinations and aber-
rant motor behaviors were absent in both groups.
Neuroimaging analysis
MRIs detected one or two small infarcts in the basal gan-
glia (n = 4), ventral posterolateral thalamic nuclei (n = 1),
cerebellum (n = 1), or brain stem (n = 2) in 3 patients in
the GADA group and 5 in the control group (p = 0.442),
but these patients were asymptomatic. The total Scheltens
scores were not significantly different (GADA 8.0 ± 8.9,
control 4.3 ± 4.2). Voxel-based morphometry did not show
any differences between the groups in either the regional
or global gray matter volume (Table 4). The average ratio
of gray matter to total intracranial volume was 0.42 ± 0.36
in the GADA group and 0.43 ± 0.34 in the control group.
Discussion
To our knowledge, this is the first study that describes the
cognitive profile of patients with GADA-positive diabetes.Table 4 The results of the MRI studies (mean (SD))
GADA Control p-values
(n = 21) (n = 19)
Total Sheltens’ score† 8.0 (8.9) 4.3 (4.2) 0.61
PVH† 1.3 (2.2) 0.6 (1.2) 0.96
WMH† 3.3 (4.9) 1.0 (2.4) 0.24
BGH† 3.1 (2.5) 2.3 (2.1) 0.59
ITF† 0.2 (0.4) 0.4 (0.8) 0.85
VBM
GMV 577 (59.9) 554 (66.6) 0.26
WMV 541.3 (80.5) 505.2 (46.0) 0.09
TIV 1365 (160.8) 1298 (104.1) 0.12
WM ratio (WM/TIV) 0.40 (0.02) 0.39 (0.02) 0.34
GM ratio (GM/TIV) 0.42 (0.04) 0.43 (0.03) 0.90
Abbreviations: GADA glutamic acid decarboxylase antibody, PVH
periventricular hyperintensities, WMH white matter hyperintensities, BGH basal
ganglia hyperintensities, ITF infratentorial foci, VBM voxel-based morphometry,
GMV gray matter volume, WMV white matter volume, TIV total intracranial
volume, WM ratio white matter ratio, GM ratio gray matter ratio.
† Mann-Whitney U test.The major outcomes suggest that patients with GADA-
positive diabetes are at a higher risk of cognitive decline
than patients with type 2 diabetes. The cognitive abilities of
diabetic patients are influenced by multiple factors [22], in-
cluding dyslipidemia [23], chronic hyperglycemia [24], re-
current severe hypoglycemic attack [25], and obesity and
hypertension [26], which may enhance the risk of cerebral
vascular disease or vascular dementia [27]. In our case-
controlled study, patients with GADA-positive diabetes
were compared to type 2 diabetics and were matched by
age and glycemic control. The insulin dose, obesity, comor-
bidity, smoking, number of cerebrovascular risk factors,
and incidence of diabetic microangiopathy in the control
group were somewhat greater than in the GADA group, al-
though white matter lesions, which are thought to be asso-
ciated with cognitive impairment in diabetics [28], were
comparable between the groups. Therefore, the patients in
the control group are at a higher risk for vascular events
and dementia.Nevertheless, the mean cognitive tests scores
were consistently lower in the GADA group. We cannot
attribute the cognitive decline detected in the present study
to the severity of diabetes or vascular involvement because
there were no differences in these factors were observed
between the groups; therefore, we propose that cognitive
impairment is associated with GADA.
The GADA-positive patients in the present study did
not exhibit any motor symptoms. Cognitive decline was
independent from other GADA-related neurological syn-
dromes, including SPS and cerebellar ataxia. The only
subtle neurological manifestation, other than cognitive im-
pairment, was a disturbance in horizontal eye motion,
which was noted in 2 patients in the GADA group. It was
also noted in the patient with GADA-associated cerebellar
ataxia, who was excluded from the present study, and our
previously published case with GADA-positive diabetes
and dementia [14]. Full range of motion and conjugate
movement indicate preserved integrity of the neural path-
way from the frontal eye field to the cranial nerves, but
a difficulty in unilateral gaze-holding suggests a dysfunc-
tion of the cerebello-vestibular system [29]. A similar phe-
nomenon was described in SPS, and disruption of
GABAergic neurons was proposed as a pathogenic mech-
anism [30]. Therefore, subtle horizontal eye motion dis-
turbance may be a specific (but not sensitive) sign
suggesting the involvement of GADA in cognitive decline.
To date, only a few GADA-related disorders, such
as stiff person plus syndrome and limbic encephalitis,
have been associated with cognitive dysfunction. Mem-
ory disturbance is a principal symptom of these disor-
ders, but the involvement of other cognitive domains
has not been thoroughly investigated. The present study
uncovered impairments in executive function, language,
general intelligence, perceptual organization, and mem-
ory in GADA-positive patients.
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mon in schizophrenic patients [31]. Recent advances have
untangled the relationship between cognitive impairment
in schizophrenic patients and the dysfunction of the
GABAergic system. The GAD67 isoform plays a key role
in schizophrenia-related cognitive impairment [32,33].
Decreased GABA levels in the prefrontal lobes are associ-
ated with the executive dysfunction and working memory
dysfunction in schizophrenia [32,34]. In addition, hippo-
campal GABAergic interneurons function in memory for-
mation by modulating pyramidal cell activity [35]. Thus,
the interrupted GABAergic system affects the modulation
of pyramidal cell activity in the cerebral cortex, which may
result in cognitive dysfunction. Although no significant
correlation was noted between serum GADA titer and
cognitive function, the impairment of GABAergic neuro-
transmission seems to have a key role. The examination of
the intrathecal GADA titer or other related antibodies
might be relevant, which were not assessed in the present
study. Despite an assumed breakdown in the cortical
GABAergic neural system, it remains unclear if the cogni-
tive tests detected specific cortical areas that were vulner-
able to decline or global cerebral damage.
Voxel-based morphometry failed to show any differ-
ences in regional or total gray matter volume between the
2 groups, moreover, neither in white matter volume. This
did not support the involvement of local or global cerebral
atrophy associated with GADA and suggests that neurode-
generative pathologies and neuronal loss have little role in
the cognitive impairment of GADA-positive patients. A
randomized control study and several case reports suggest
that GADA-associated neurological manifestations are
reversible and are successfully treated by immunomodu-
lating therapy [36,37]. If this is the case, the cognitive im-
pairment can be resolved in a similar fashion. Further
studies are needed to confirm this hypothesis.
The present study is not without limitations. The se-
lection process used in clinic-based recruiting may bias
the subject pool. In addition, previous neurological or
psychiatric disease history might exclude meaningful pa-
tients from both groups. Because of the exploratory na-
ture of this study, we did not perform any corrections
for multiple comparisons. As the present study was
cross-sectional, no information was available concerning
the prognosis of cognitive decline, such as whether it
was progressive or underwent spontaneous remission.
Moreover, this study did not provide direct evidence for
the CNS involvement of GADA, such as the intrathecal
synthesis of GADA.
Conclusions
In summary, we found that patients with GADA-positive
diabetes are at a higher risk for cognitive decline than
those with GADA-negative type 2 diabetes of comparablediabetic severity. GADA may mediate cognitive dysfunc-
tion by disrupting GABA production and may contribute
to dementia in diabetics. Further studies, including cohort
studies and longitudinal studies, are required to uncover
the mechanism in more detail.
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